Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
With both Shingrix doses, he had injection site pain,; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 70-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix with an associated reaction of injection site pain (For tolerance to 1st dose, refer case US2026010075). On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site pain (Verbatim: With both Shingrix doses, he had injection site pain,). The outcome of the injection site pain was resolved. It was unknown if the reporter considered the injection site pain to be related to Shingrix. It was unknown if the company considered the injection site pain to be related to Shingrix. Linked case(s) involving the same patient: US2026010075 Additional Information: GSK Receipt Date: 21-JAN-2026 With both Shingrix doses, he had experienced injection site pain, which was more than with other types of vaccines. No other adverse events had been reported The batch number was not provided, and we are unable to contact the reporter.; Sender's Comments: US-GSK-US2026010075:same patient